Review of Botulinum Toxin Use and Outcomes in Adults with Hemiplegia Aged 18 to 75

What this Trial Is About

Researchers are evaluating the medical records of hemiplegic patients who received botulinum toxin treatment to better understand muscle selection, dosage, and clinical outcomes. This retrospective study includes 35 patients treated between 2017 and 2020 at the Physical Medicine and Rehabilitation outpatient clinic of Istanbul Physical Medicine and Rehabilitation Training and Research Hospital. The study focuses on patients with hemiplegia who received botulinum toxin injections for spasticity in the upper andor lower limbs. The study involves reviewing recorded data from two time points spaced six months apart for each patient. Data collected include sociodemographic and clinical information, stroke-related characteristics, botulinum toxin dosage, injected muscle groups, medications, and comorbidities. Functional assessments such as the Functional Independence Measure FIM and Brunnstrom stage, along with spasticity evaluations using the Modified Ashworth Scale and Global Spasticity Index, are analyzed to assess treatment effects. Participants involvement consists of data collection from existing medical records without active intervention. Researchers monitor changes in spasticity severity as the primary outcome, along with secondary measures including the Global Spasticity Index, Functional Independence Measure, Brunnstrom stage, and details on injected muscles and dosage. The study is observational and retrospective, focusing on analyzing clinical outcomes from past treatment records.

Botulinum Toxin Applications in Hemiplegic Patients